Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Neoplasms 1Hypertension 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Diabetes Mellitus, Type 2 1Cushing Syndrome 1Carcinoma, Pancreatic Ductal 1Adrenocortical Carcinoma 1Adrenal Cortex Neoplasms 1Adenocarcinoma 1ACTH Syndrome, Ectopic 1

Interventions

durvalumab 3abemaciclib 3Fulvestrant 3Cisplatin 3ribociclib 2pembrolizumab 2palbociclib 2Pemetrexed 2Nivolumab 2Letrozole 2Carboplatin 2Bevacizumab 2Anastrozole 2130-nm albumin-bound paclitaxel 2selpercatinib 1selinexor 1repotrectinib 1relatlimab 1relacorilant 1olaparib 1gallium 68 PSMA-11 1exemestane 1enfortumab vedotin 1elacestrant 1darolutamide 1cemiplimab 1atezolizumab 1Tamoxifen 1Sunitinib 1STX-478 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × relacorilant × 90 days × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡